scholarly journals Evaluation of the prevalence and severity of xerophthalmia in head and neck cancers patients undergoing curative radiotherapy

2016 ◽  
Vol 14 (4) ◽  
Author(s):  
Sowmya V ◽  
Dipika Jayachander ◽  
Vijna Kamath ◽  
Mithun SK Rao ◽  
Mohammed Raees Tonse ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Keratoconjunctivitis Sicca ◽  
Study Objective ◽  
Cancer Group ◽  
Curative Radiotherapy ◽  
Significant Difference ◽  
Rectal Cancers

  Background: The study objective was to assess the development of xerophthalmia [dry eye syndrome (DES) or keratoconjunctivitis sicca] in head and neck cancer patients undergoing radiotherapy.Methods: Twenty two head and neck cancer patients requiring more than 60 Gy of curative radiotherapy/chemoradiotherapy and ten patients requiring radiotherapy/ chemoradiotherapy for treating cancers in the non head and neck regions (like breast, oesophagus, prostate, cervix and rectal cancers) were also enrolled in the study. The development of DES was studied at the beginning (day 0, before the start of radiotherapy) at day 21 (after completion of 30 Gy) and on completion of the treatment (> 60 Gy). As a comparative cohort, people with non head and neck cancer needing curative radiotherapy were also evaluated for comparison.Results: There was no difference in degree of DES between the Head and Neck cancer cohorts and non head and neck group at the beginning of treatment. However there was a statistically significant difference (p < 0.001) between the two groups at both mid and end of RT time point. Inter comparison between the various time points in the head and neck cancer group showed that the incidence of DES increased with the radiation exposure and was significant (pre to mid p < 0.001; and mid to end p < 0.005). A negative (r = -0.262) correlation was seen between DES and distance.Conclusions: The study showed that lesser the distance from the epicenter of the radiation to the orbital rim more was the severity of DES.

Evaluation of Efficacy of an Herbal Compound on Dry Mouth in Patients With Head and Neck Cancers

2015 ◽  
Vol 21 (1) ◽  
pp. 30-33 ◽  
Author(s):  
Ahmad Ameri ◽  
Ghazaleh Heydarirad ◽  
Hossein Rezaeizadeh ◽  
Rasool Choopani ◽  
Ali Ghobadi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Visual Analog Scale ◽  
Neck Cancer ◽  
Head And Neck Cancers ◽  
Dry Mouth ◽  
Analog Scale ◽  
Significant Difference ◽  
Herbal Compound

Dry mouth is a common complication of radiotherapy for head and neck cancers. This study compared the efficacy of an herbal compound containing Malva sylvestris and Alcea digitata (Boiss) with artificial saliva (Hypozalix) for improving the symptoms of dry mouth in head and neck cancer patients. The study examined a total of 62 subjects assigned to 2 groups. The herbal compound and Hypozalix were administered for 4 weeks. Efficacy was assessed using the visual analog scale and by grading the degree of dry mouth. Both groups showed a significant difference between visual analog scale before and following intervention. There was also a significant difference in visual analog scale between groups at 4 weeks after onset of intervention. The herbal group showed a significant difference between the grade of dry mouth before and after intervention, but no change was observed for grade of dry mouth in the Hypozalix group. This study supports the efficacy of the herbal compound for controlling symptoms of dry mouth in head and neck cancer patients.

scholarly journals ЦИТОГЕНЕТИЧНІ ПОШКОДЖЕННЯ ХРОМАТИДНОГО ТИПУ ТА ГЕНОМНІ ПОРУШЕННЯ У ЛІМФОЦИТАХ ОНКОЛОГІЧНИХ ПАЦІЄНТІВ З РІЗНОЮ ЛОКАЛІЗАЦІЄЮ ПУХЛИН ПРИ ПРОМЕНЕВІЙ ТЕРАПІЇ

2019 ◽  
pp. 110-120
Author(s):  
Т. С. Сипко
Keyword(s):  
Lung Cancer ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Tumor Localization ◽  
Damage Level ◽  
Lung Cancer Patients ◽  
Significant Difference ◽  
Chromatid Aberrations

The article showed the study of chromatid type aberrations and genome abnormalities in 65 cancer patients at the stages of radiotherapy depending on tumor localization. Оncogynecological patients (with cancer in female reproductive system), lung cancer patients and head and neck cancer patients were examined before treatment, in the middle and at the end of the radiotherapy course. The over-spontaneous level of chromatid type aberrations and genomic abnormalities in cancer patients before the radiotherapy start was noted. The highest level of chromatid type aberrations before treatment was observed in lung cancer patients. No significant changes in the level of chromatid aberrations in oncogynecological patients during the whole radiotherapy course were detected. In the middle of treatment there was a significant frequency increase of chromatid type aberrations in head and neck cancer patients compared with pre-radiotherapy values of these parameters. This increase disappeared at the end of the radiotherapy course. In contrast to oncogynecological cancer patients and head and neck cancer patients in the group of lung cancer patients there was a significant increase of chromatid type damage level from the beginning to the end of the radiotherapy. The accumulation of radiation-non-specific rearrangements was mainly due to chromatid fragments, and the level of chromatid exchanges remained unchanged during the radiotherapy. The frequency variations of genome abnormalities, such as hyperploids and endoreplications, fluctuated in all patient groups. Concerning the polyploid cells, a significant difference at all stages of the study was observed in oncogynecological patients. The research of chromatid type aberrations and genome abnormalities showed some different features in changes of these parameters depending on tumor localization. The obtained data complemented the knowledge about the general cytogenetic status of cancer patients and are important for determining the influence of such a factor as tumor localization on the formation and dynamics of radiation-non-specific chromatid type lesions and genomic abnormalities during a radiotherapy course.

scholarly journals A beállítási biztonsági margó nagyságának meghatározása fej-nyak daganatok 2D-2D és 3D képvezérelt intenzitásmodulált sugárkezelése esetén

2018 ◽  
Vol 159 (29) ◽  
pp. 1193-1200
Author(s):  
Péter Kovács ◽  
Evelin Szita ◽  
Kitti Schvarcz ◽  
Szabolcs Kamu ◽  
Judit Kalincsák ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Image Registration ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Target Volume ◽  
Setup Error ◽  
Error Determination ◽  
Imaging Time ◽  
Significant Difference

Abstract: Introduction: Image-guided intensity-modulated radiation therapy is essential for oncology treatment of head-and-neck cancer patients. Aim: MV-kV and CBCT modalities were compared in case of IGRT treatment for head-and-neck cancer patients. Setup error, setup margin (SM), imaging and evaluation times and imaging doses were analyzed. Method: Eight patients’ elective treatment was evaluated, 66 orthogonal MV-kV images and 66 CBCT series were acquired. Setup error measurement was based on bony manual image registration in three translational directions. Normality test and F-test were performed followed by the comparison with independent-samples T-test (p<0,05). The necessary target volume setup margin was calculated based on Van Herk’s equation. Imaging time and setup error determination time were measured. Imaging doses were estimated based on the literature. Results: No statistically significant difference was found between setup errors determined by MV-kV and CBCT (VRT: 0.5 mm, SD = 1.9 vs. 0.4 mm, SD = 2.1, p = 0.371; LNG: 0.2 mm, SD = 2.2 vs. –0.1 mm, SD = 2.2, p = 0.188; LAT: 0.2 mm, SD = 2.2 vs. 0.3 mm, SD = 2.1, p = 0.41). SM values were: VRT: 2.7 mm vs. 2.5 mm; LNG: 2.1 mm vs. 1.3 mm; LAT: 2.2 mm vs. 2.3 mm. Mean imaging time was 0.65 min (MV-kV) vs. 2.29 min (CBCT). Mean setup error determination time was 2.41 min for both modalities. Estimated imaging doses were 6.88 mGy (MV-kV) vs. 17.2 mGy (CBCT) per fraction. Conclusion: The bony anatomy derived image registration based translational setup error determination results in similar values either by MV-kV or by CBCT. Using 3 mm setup margin in all the directions might be adequate. Imaging time is less by MV-kV, significant difference in imaging doses did not appear. Using CBCT is generally suggested. MV-kV might be an alternative in case of need for shortened imaging time. Orv Hetil. 2018; 159(29): 1193–1200.

Prevention of cisplatin nephrotoxicity (CN) in head and neck cancer patients receiving concurrent chemoradiation (CCRT) by adding oral rehydration solution (ORS) to short hydration regimen: A randomized open-label controlled trial.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18560-e18560
Author(s):  
Aungsumal Maisrikrod ◽  
Siwat Sakdejayont ◽  
Jakkapan Rongmuang ◽  
Chirawadee Sathitruangsak ◽  
Patrapim Sunpaweravong ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Sample Size ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Control Group ◽  
Open Label ◽  
Total Fluid Intake ◽  
Significant Difference

e18560 Background: CN remains a frequent occurrence despite receiving standard fluid hydration, particularly for head and neck cancer patients undergoing CCRT. We aimed to investigate whether adding ORS to short hydration regimen can reduce CN. Methods: We conducted a randomized open-label controlled trial in patients with head and neck cancer receiving CCRT with 3-weekly cisplatin (≥ 60 mg/m²). Eligible patients were randomly assigned to receive short hydration regimen (2000 mL of normal saline on day 1) alone or in combination with 2000 mL of ORS on days -1, 2 and 3 of each cycle. All patients were instructed to drink at least 2000 mL of fluid. The primary end point was the incidence of ≥ gr 1 creatinine (Cr) elevation on day 8. The planned sample size was 160 (80 patients each arm). Results: Thirty-five patients in ORS group and 34 patients in control group (43% of planned sample size) were enrolled. Baseline characteristics were balanced between the two groups, except more patients in ORS group underwent surgery (35.3% vs. 22.9%), and had less feeding tube prophylaxis (76.5% vs. 88.6%), although there were not statistically significant. The mean dose of cisplatin on day 1 was significantly higher in ORS group (91.2 mg/m2 vs. 85.1 mg/m2, p=0.01). There was no difference of volume of total fluid intake and toxicities between the two groups. Less percentage of patients in ORS group developed ≥ gr 1 Cr elevation as shown in the Table, although there were not statistically significant. Conclusions: Although our interim analysis showed no significant difference of CN between the groups, there was a trend that addition of ORS might prevent acute and chronic kidney injury secondary to cisplatin. The completed enrollment is warranted to confirm this early findings. Clinical trial information: TCTR20200207005 . [Table: see text]

A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24124-e24124
Author(s):  
Sachin Babanrao Dhumal ◽  
Vanita Noronha ◽  
Vijay Maruti Patil ◽  
Amit Joshi ◽  
Nandini Sharrel Menon ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Head And Neck Cancer ◽  
Adverse Events ◽  
Head And Neck ◽  
Renal Dysfunction ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Phase Iii ◽  
Controlled Study ◽  
Significant Difference

e24124 Background: Oral mucositis related pain during CTRT in head and neck cancers is a common problem. Unfortunately, in spite of it being common, there is limited evidence for selection of systemic analgesic in this situation. Hence, this study was designed to compare the analgesic effect of an NSAID (diclofenac) versus a weak opioid (tramadol). Methods: This was an open-label, parallel design, superiority randomized controlled study. In this study head and neck cancer patients undergoing radical or adjuvant chemoradiation, who had grade 1 or above mucositis (in accordance with CTCAE version 4.03) and had pain related to it were randomly assigned to either diclofenac or tramadol for mucositis related pain control. The primary endpoint was analgesia after the 1st dose. The secondary endpoints were the rate of change in analgesic within 1 week, adverse events, and quality of life. Results: 128 patients were randomized, 66 in diclofenac and 62 in tramadol arm. The median AUC for the diclofenac arm and the tramadol arm were 348.936 units (Range 113.64-1969.23) & 420.87 (101.97-1465.96) respectively (p = 0.05619). Five patients (8.1%) in the tramadol arm and 11 patients (16.7%) in the diclofenac arm required a change in analgesic within 1 week of starting the analgesic (p = 0.184). There was no statistically significant difference in any adverse events between the 2 arms. However, the rate of any grade of renal dysfunction was numerically higher in diclofenac arm (10.6% versus 4.8%, p = 0.326). Conclusions: In this phase 3 study, evaluating diclofenac and tramadol for Chemoradiation induced mucositis pain, the analgesic efficacy of both analgesics was found to be similar but diclofenac was associated with a higher rate of renal dysfunction. Clinical trial information: CTRI/2016/09/007302 .

Sign in / Sign up

Export Citation Format

Share Document